Korean J Gastroenterol.  2011 Jan;57(1):54-55. 10.4166/kjg.2011.57.1.54.

Histamine2-Receptor Antagonists Are an Alternative to Proton Pump Inhibitor in Patients Receiving Clopidogrel. Gastroenterology 2010;139:1165-1171

• Kim SG

• KMID: 991471
• DOI: http://doi.org/10.4166/kjg.2011.57.1.54

Abstract

No abstract available.

Reference

References

1. Wu CY, Chan FK, Wu MS, et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology. 2010; 139:1165–1171.

2. Ng FH, Lam KF, Wong SY, et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77:173–177.

3. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008; 103:2890–2907.

4. Hulot IS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108:2244–2247.

5. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008; 48:475–484.

6. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937–944.

7. FDA 2009 October 5. Available at:. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvidersDrugSafetyInformationforHealthcareProfessionals/ucm079520.htm. Accessed November 25, 2009.

8. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360:363–375.

9. Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 2010; 104:626–632.